Current Study
Cardiovascular | PREVENT_HF
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Evaluate the Effect of Drug X in Combination with Dapagliflozin Compared with Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure
Study Status
Recruiting
Duration
Up to 2 years
Clinic Visits
Up to 11
Phone Check-ins
0
Study Overview
Location
Osborne Park
Phase
Phase III
Study Duration
Up to 2 years
Main Entry Criteria
- Over 40 years of age
- Established Cardiovascular disease
- Diagnosed with T2DM (Type 2 Diabetes Mellitus) and requiring treatment
There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.
Main Exclusion Criteria
Assessments
- ECG
- Blood pressure and pulse
- Blood and urine tests
At a Glance
Clinic Visits
Up to 11
Phone Calls
0
Duration
Up to 2 years